ArticleThe Journal of investigative dermatology2012
Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.
Article in The Journal of investigative dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Scalable spatial single-cell transcriptomics and translatomics in 3D thick tissue blocks.Nature methods · 2025Article
- Exploring the Complexity of Cutaneous Squamous CellCarcinoma Microenvironment: Focus on Immune Cell Roles by Novel 3D In Vitro Models.Life (Basel, Switzerland) · 2025Review
- From neglect to necessity: the role of innate immunity in cutaneous squamous cell carcinoma therapy.Frontiers in immunology · 2025Review
- Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).Cells · 2024Review
- The roles of tissue resident macrophages in health and cancer.Experimental hematology & oncology · 2024Review
- Gene expression levels associated with impaired immune response and increased proliferation could serve as biomarkers for women following cervical cancer screening programmes.Frontiers in immunology · 2024Article
- Understanding the squamous cell carcinoma immune microenvironment.Frontiers in immunology · 2023Review
- Review
- Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021Review
- A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.British journal of cancer · 2021Article
- Article
- The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021Review
- The role of transforming growth factor-beta in immune suppression and chronic inflammation of squamous cell carcinomas.Molecular carcinogenesis · 2020Review
- Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma.NPJ precision oncology · 2020Article
- The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2019Review
- The Dynamics of the Skin's Immune System.International journal of molecular sciences · 2019Review
- Langerhans Cells: Sensing the Environment in Health and Disease.Frontiers in immunology · 2018Review
- Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma.Dermatologic clinics · 2017Review
- Skin response to a carcinogen involves the xenobiotic receptor pregnane X receptor.Experimental dermatology · 2015Article
- Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Langerhans cells (LCs) are dendritic cells (DCs) localized to the epidermis. They should be the first antigen-presenting cells to encounter squamous cell carcinoma (SCC). The aim of this study was to investigate the ability of LCs isolated from human SCC to induce T-cell proliferation and polarization. We investigated the ability of LCs from SCC and peritumoral skin to induce T-cell proliferation and polarization. We also studied the effect of SCC supernatant on the ability of LCs from normal skin, in vitro-generated LCs, and DCs to activate and polarize T cells. LCs from SCC were stronger inducers of allogeneic CD4(+) and CD8(+) T-cell proliferation and IFN-γ production than LCs from peritumoral skin. We found that tumor supernatants (TSNs) were rich in immunosuppressive cytokines; despite this, allogeneic CD4(+) and CD8(+) T-cell proliferation and IFN-γ induction by LCs were augmented by TSN. Moreover, TSN facilitated IFN-γ induction by in vitro-generated LCs, but suppressed the ability of in vitro-generated DCs to expand allogeneic CD4(+) and CD8(+) T cells. We have demonstrated that LCs from SCC can induce type 1 immunity. TSN induces IFN-γ induction by in vitro-generated LCs. This contrasts greatly with prior studies showing that DCs from SCC cannot stimulate T cells. These data indicate that LCs may be superior to DCs for SCC immunotherapy and may provide a new rationale for harnessing LCs for the treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.